Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-05-2024 | Colorectal Cancer | Research

LAMP2A regulates cisplatin resistance in colorectal cancer through mediating autophagy

Authors: Zhiliang Shi, Shuting Yang, Chenglong Shen, Jiazhe Shao, Fang Zhou, Haichen Liu, Guoqiang Zhou

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2024

Abstract

Background

Drug resistance is an important constraint on clinical outcomes in advanced cancers. LAMP2A is a limiting protein in molecular chaperone-mediated autophagy. This study was aimed to explore LAMP2A function in cisplatin (cis-diamminedichloroplatinum, DDP) resistance colorectal cancer (CRC) to seek new ideas for CRC clinical treatment.

Methods

In this study, LAMP2A expression was analyzed by molecular experimental techniques,such as qRT-PCR and western blot. Then, LAMP2A in cells was interfered by cell transfection experiments. Subsequently, the function of LAMP2A on proliferation, migration, invasion, DDP sensitivity, and autophagy of CRC/DDP cells were further investigated by a series of experiments, such as CCK-8, transwell, and western blot.

Results

We revealed that LAMP2A was clearly augmented in DDP-resistant CRC and was related to poor patient prognosis. Functionally, LAMP2A insertion remarkably CRC/DDP proliferation, migration, invasion ability and DDP resistance by strengthen autophagy. In contrast, LAMP2A knockdown limited the proliferation, migration, and invasion while heightened cellular sensitivity to DDP by restraining autophagy in CRC/DDP cells. Furthermore, LAMP2A silencing was able to curb tumor formation and enhance sensitivity to DDP in vivo.

Conclusion

In summary, LAMP2A boosted malignant progression and DDP resistance in CRC/DDP cells through mediating autophagy. Clarifying LAMP2A function in DDP resistance is promising to seek cancer therapies biomarkers targeting LAMP2A activity.

Auzmendi-Iriarte J, Otaegi-Ugartemendia M, Carrasco-Garcia E, Azkargorta M, Diaz A, Saenz-Antoñanzas A, Andermatten JA, Garcia-Puga M, Garcia I, Elua-Pinin A, Ruiz I, Sampron N, Elortza F, Cuervo AM, Matheu A (2022) Chaperone-mediated autophagy controls proteomic and transcriptomic pathways to maintain glioma stem cell activity. Cancer Res 82:1283–1297. https://doi.org/10.1158/0008-5472.Can-21-2161CrossRefPubMedPubMedCentral

Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM (2008) The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol 28:5747–5763. https://doi.org/10.1128/mcb.02070-07CrossRefPubMedPubMedCentral

Cuervo AM, Dice JF (2000) Regulation of lamp2a levels in the lysosomal membrane. Traffic 1:570–583. https://doi.org/10.1034/j.1600-0854.2000.010707.xCrossRefPubMed

Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. https://doi.org/10.1016/j.ejphar.2014.07.025CrossRefPubMedPubMedCentral

Desideri E, Castelli S, Dorard C, Toifl S, Grazi GL, Ciriolo MR, Baccarini M (2023) Impaired degradation of YAP1 and IL6ST by chaperone-mediated autophagy promotes proliferation and migration of normal and hepatocellular carcinoma cells. Autophagy 19:152–162. https://doi.org/10.1080/15548627.2022.2063004CrossRefPubMed

Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221:3–12. https://doi.org/10.1002/path.2697CrossRefPubMedPubMedCentral

Heckmann BL, Green DR (2019) LC3-associated phagocytosis at a glance. J Cell Sci. https://doi.org/10.1242/jcs.222984CrossRefPubMedPubMedCentral

Ichikawa A, Fujita Y, Hosaka Y, Kadota T, Ito A, Yagishita S, Watanabe N, Fujimoto S, Kawamoto H, Saito N, Yoshida M, Hashimoto M, Minagawa S, Hara H, Motoi N, Yamamoto Y, Ochiya T, Araya J, Kuwano K (2020) Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer. Cancer Sci 111:4154–4165. https://doi.org/10.1111/cas.14629CrossRefPubMedPubMedCentral

Kaushik S, Cuervo AM (2018) The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol 19:365–381. https://doi.org/10.1038/s41580-018-0001-6CrossRefPubMedPubMedCentral

Khan SU, Pathania AS, Wani A, Fatima K, Mintoo MJ, Hamza B, Paddar MA, Bhumika W, Anand LK, Maqbool MS, Mir SA, Kour J, Venkateswarlu V, Mondhe DM, Sawant SD, Malik F (2022) Author correction: activation of lysosomal mediated cell death in the course of autophagy by mTORC1 inhibitor. Sci Rep 12:8772. https://doi.org/10.1038/s41598-022-12521-wCrossRefPubMedPubMedCentral

Khan SU, Fatima K, Malik F, Kalkavan H, Wani A (2023) Cancer metastasis: molecular mechanisms and clinical perspectives. Pharmacol Ther 250:108522. https://doi.org/10.1016/j.pharmthera.2023.108522CrossRefPubMed

Kiffin R, Christian C, Knecht E, Cuervo AM (2004) Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell 15:4829–4840. https://doi.org/10.1091/mbc.e04-06-0477CrossRefPubMedPubMedCentral

Kon M, Kiffin R, Koga H, Chapochnick J, Macian F, Varticovski L, Cuervo AM (2011) Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med 3:109ra117. https://doi.org/10.1126/scitranslmed.3003182CrossRefPubMedPubMedCentral

Lamark T, Svenning S, Johansen T (2017) Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays Biochem 61:609–624. https://doi.org/10.1042/ebc20170035CrossRefPubMed

Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C (2020a) Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification. Drug Resist Updat 53:100720. https://doi.org/10.1016/j.drup.2020.100720CrossRefPubMed

Li X, He S, Ma B (2020b) Autophagy and autophagy-related proteins in cancer. Mol Cancer 19:12. https://doi.org/10.1186/s12943-020-1138-4CrossRefPubMedPubMedCentral

Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, Buchan JR, Cho WC (2017) Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. https://doi.org/10.3390/ijms18020367CrossRefPubMedPubMedCentral

Liu H, Yong Y, Li X, Ye P, Tao K, Peng G, Mo M, Guo W, Chen X, Luo Y, Lin Y, Qiu J, Zhang Z, Ding L, Zhou M, Yang X, Lu L, Yang Q, Xu P (2022) Chaperone-mediated autophagy regulates cell growth by targeting SMAD3 in glioma. Neurosci Bull 38:637–651. https://doi.org/10.1007/s12264-022-00818-9CrossRefPubMedPubMedCentral

Luo Y, Zheng S, Wu Q, Wu J, Zhou R, Wang C, Wu Z, Rong X, Huang N, Sun L, Bin J, Liao Y, Shi M, Liao W (2021) Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy 17:4083–4101. https://doi.org/10.1080/15548627.2021.1901204CrossRefPubMedPubMedCentral

Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB, Zhang LC, Li L (2023) Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med 12:11073–11096. https://doi.org/10.1002/cam4.5594CrossRefPubMedPubMedCentral

Makovec T (2019) Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 53:148–158. https://doi.org/10.2478/raon-2019-0018CrossRefPubMedPubMedCentral

Ming H, Li B, Jiang J, Qin S, Nice EC, He W, Lang T, Huang C (2023) Protein degradation: expanding the toolbox to restrain cancer drug resistance. J Hematol Oncol 16:6. https://doi.org/10.1186/s13045-023-01398-5CrossRefPubMedPubMedCentral

Mizushima N, Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3:542–545. https://doi.org/10.4161/auto.4600CrossRefPubMed

Peña-Martinez C, Rickman AD, Heckmann BL (2022) Beyond autophagy: LC3-associated phagocytosis and endocytosis. Sci Adv 8:eabn1702. https://doi.org/10.1126/sciadv.abn1702CrossRefPubMedPubMedCentral

Peng JQ, Han SM, Chen ZH, Yang J, Pei YQ, Bao C, Qiao L, Chen WQ, Liu B (2020) Chaperone-mediated autophagy regulates apoptosis and the proliferation of colon carcinoma cells. Biochem Biophys Res Commun 522:348–354. https://doi.org/10.1016/j.bbrc.2019.11.081CrossRefPubMed

Qiao L, Hu J, Qiu X, Wang C, Peng J, Zhang C, Zhang M, Lu H, Chen W (2023) LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles. Autophagy 19:2837–2852. https://doi.org/10.1080/15548627.2023.2235196CrossRefPubMedPubMedCentral

Shen J, Liang C, Su X, Wang Q, Ke Y, Fang J, Zhang D, Duan S (2022) Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis. Biomark Res 10:72. https://doi.org/10.1186/s40364-022-00419-8CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654CrossRefPubMed

Song M, Cui M, Liu K (2022) Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem 232:114205. https://doi.org/10.1016/j.ejmech.2022.114205CrossRefPubMed

Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e838. https://doi.org/10.1038/cddis.2013.350CrossRefPubMedPubMedCentral

Tokarchuk I, Janser FA, Schläfli AM, Pinto MT, Humbert M, Niklaus NJ, Berezowska S, Langer R, Tschan MP (2021) Increased LAMP2A levels correlate with a shorter disease-free survival of HER2 negative breast cancer patients and increased breast cancer cell viability. Biochem Biophys Res Commun 569:47–53. https://doi.org/10.1016/j.bbrc.2021.06.082CrossRefPubMed

Vargas JNS, Hamasaki M, Kawabata T, Youle RJ, Yoshimori T (2023) The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol 24:167–185. https://doi.org/10.1038/s41580-022-00542-2CrossRefPubMed

Wang R, Liu Y, Liu L, Chen M, Wang X, Yang J, Gong Y, Ding BS, Wei Y, Wei X (2019) Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. EBioMedicine 40:118–134. https://doi.org/10.1016/j.ebiom.2019.01.045CrossRefPubMedPubMedCentral

Wang Y, Wang Y, Qin Z, Cai S, Yu L, Hu H, Zeng S (2021) The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol 17:291–306. https://doi.org/10.1080/17425255.2021.1887139CrossRefPubMed

Wani A, Gupta M, Ahmad M, Shah AM, Ahsan AU, Qazi PH, Malik F, Singh G, Sharma PR, Kaddoumi A, Bharate SB, Vishwakarma RA, Kumar A (2019) Alborixin clears amyloid-β by inducing autophagy through PTEN-mediated inhibition of the AKT pathway. Autophagy 15:1810–1828. https://doi.org/10.1080/15548627.2019.1596476CrossRefPubMedPubMedCentral

Wani A, Al Rihani SB, Sharma A, Weadick B, Govindarajan R, Khan SU, Sharma PR, Dogra A, Nandi U, Reddy CN, Bharate SS, Singh G, Bharate SB, Vishwakarma RA, Kaddoumi A, Kumar A (2021a) Crocetin promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway. Autophagy 17:3813–3832. https://doi.org/10.1080/15548627.2021.1872187CrossRefPubMedPubMedCentral

Wani A, Zhu J, Ulrich JD, Eteleeb A, Sauerbeck AD, Reitz SJ, Arhzaouy K, Ikenaga C, Yuede CM, Pittman SK, Wang F, Li S, Benitez BA, Cruchaga C, Kummer TT, Harari O, Chou TF, Schröder R, Clemen CS, Weihl CC (2021b) Neuronal VCP loss of function recapitulates FTLD-TDP pathology. Cell Rep 36:109399. https://doi.org/10.1016/j.celrep.2021.109399CrossRefPubMedPubMedCentral

Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 14:101174. https://doi.org/10.1016/j.tranon.2021.101174CrossRefPubMedPubMedCentral

Xie W, Zhang L, Jiao H, Guan L, Zha J, Li X, Wu M, Wang Z, Han J, You H (2015) Chaperone-mediated autophagy prevents apoptosis by degrading BBC3/PUMA. Autophagy 11:1623–1635. https://doi.org/10.1080/15548627.2015.1075688CrossRefPubMedPubMedCentral

Xuan Y, Zhao S, Xiao X, Xiang L, Zheng HC (2021) Inhibition of chaperone-mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Mol Med Rep. https://doi.org/10.3892/mmr.2021.11999CrossRefPubMedPubMedCentral

Zhou J, Yang J, Fan X, Hu S, Zhou F, Dong J, Zhang S, Shang Y, Jiang X, Guo H, Chen N, Xiao X, Sheng J, Wu K, Nie Y, Fan D (2016) Chaperone-mediated autophagy regulates proliferation by targeting RND3 in gastric cancer. Autophagy 12:515–528. https://doi.org/10.1080/15548627.2015.1136770CrossRefPubMedPubMedCentral

Title: LAMP2A regulates cisplatin resistance in colorectal cancer through mediating autophagy
Authors: Zhiliang Shi
Shuting Yang
Chenglong Shen
Jiazhe Shao
Fang Zhou
Haichen Liu
Guoqiang Zhou
Publication date: 01-05-2024
Publisher: Springer Berlin Heidelberg
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-024-05775-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib

Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990–2019

Clinical significance of 18F-FDG-PET/CT for detection of incidental pre-malignant and malignant colonic lesions: correlation with colonoscopic and histopathological results

Endoscopic submucosal dissection versus surgery for T1b esophageal carcinoma: a single-center retrospective study

A perspective on tumor radiation resistance following high-LET radiation treatment

The emerging role and mechanism of HMGA2 in breast cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials